Bevacizumab (Bev)-based combination therapy across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC)-interim analysis results from a German non-interventional study (KORALLE).

27. Oktober 2017

Eggers, E., Uhlig, J., Reichert, D., Wein, A., Schulz, H., Behringer, A., Arnold, D., 2017.

Oncol Res Treat, 40(suppl 3)(P577), 162-163.